Literatür

BAŞLIKYAZARLARYAYINTARİH
177Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical ResultsBaum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, Osterkamp F, Reineke U, Smerling CJournal of Nuclear Medicine
68Ga-PSMA PET/CT Revealing Unusual Inguinal Canal and Distant Nodal Metastasis in a Case of Castration-Resistant Prostate Cancer.Vadi SK, Kumar R, Mittal BR, Singh H, Singh SK.Journal of Clinical Nuclear Medicine
Small Lymph Node Metastasis Detected by 68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer.Chaussé G, Abikhzer G, Probst S.Journal of Clinical Nuclear Medicine
Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms.Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, Hommann M, Robiller FC, Niepsch K, Franz H, Jochems A, Lambin P, Hörsch D.Oncotarget
Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H.European Journal of Nuclear Medicine and Molecular Imaging
68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy PlanningCalais J, Czernin J, Cao M, Kishan A, Hegde J et al.Journal of Nuclear Medicine
Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Swimmer-Plot analysis suggests efficacy regarding duration of tumor-control.Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A.Journal of Nuclear Medicine
Current status of theranostics in prostate cancer.Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C.European Journal of Nuclear Medicine and Molecular Imaging
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T.European Journal of Nuclear Medicine and Molecular Imaging
Prostate-specific membrane antigen theranostics: therapy with lutetium-177.Ferdinandus J, Violet J, Sandhu S, Hofman MSCurrent Opinion in Urology